Sebastien Jeay

Allschwil, BL 4123, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Discovery of Novel Aminopyrimidines as Selective EP2 Receptor Antagonists.

Discovery of Novel Aminopyrimidines as Selective EP2 Receptor Antagonists.

Journal: ChemMedChem

Published: February 13, 2025

Discovery of ACT-1002-4271 as a Dual Prostaglandin E2 Receptor 2/Prostaglandin E2 Receptor 4 Antagonist with In Vivo Anti-Tumor Efficacy.

Discovery of ACT-1002-4271 as a Dual Prostaglandin E2 Receptor 2/Prostaglandin E2 Receptor 4 Antagonist with In Vivo Anti-Tumor Efficacy.

Journal: ChemMedChem

Published: February 13, 2025

Design of Dual EP2/EP4 Antagonists through Scaffold Merging of Selective Inhibitors.

Design of Dual EP2/EP4 Antagonists through Scaffold Merging of Selective Inhibitors.

Journal: ChemMedChem

Published: November 01, 2023

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

Journal: Journal of medicinal chemistry

Published: March 30, 2022

Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.

Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.

Journal: British journal of cancer

Published: November 23, 2020

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.

Journal: Bioorganic & medicinal chemistry letters

Published: June 28, 2018

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Journal: Cancer research

Published: February 02, 2018

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 08, 2017

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Journal: Cell reports

Published: September 27, 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Journal: Cancer cell

Published: August 02, 2016

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

Journal: eLife

Published: July 04, 2016

Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.

Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.

Journal: Bioorganic & medicinal chemistry letters

Published: June 20, 2016

Showing 1-12 of 23

Last Updated: 09/26/2026